Home/Pipeline/GlyT2 Inhibitor Program

GlyT2 Inhibitor Program

Neurological Disorders

DiscoveryActive

Key Facts

Indication

Neurological Disorders

Phase

Discovery

Status

Active

Company

Micar Innovation

About Micar Innovation

Micar Innovation is a private, pre-revenue biotech company providing AI-powered computational drug discovery services and developing its own internal pipeline. Its core technology platform integrates advanced molecular modeling, dynamics, and free energy calculations to de-risk and accelerate early-stage drug discovery, claiming to reduce the timeline for entire discovery processes to 2-8 weeks. The company targets orphan GPCRs, understudied proteins, and rare diseases, and has demonstrated its capabilities through published research on SARS-CoV-2 variants and partnerships for medicinal cosmetics development.

View full company profile

Therapeutic Areas

Rare Diseases Metabolic Disorders Oncology Neurological Disorders Infectious Diseases Cardiovascular

Other Neurological Disorders Drugs

Drug	Company	Phase	Status
Biomarker Development Program	NeuroVision Imaging	Research	Active
Biomarker Discovery & Validation Services	NeuroDex	Service	Active
Clinical Trial Biomarker Support	NeuroDex	Service	Active
CNS-Targeting Capsids	rAAVen Therapeutics	Pre-clinical	Active
IVL-002	InVirtuoLabs	Discovery	Active
IVL-003	InVirtuoLabs	Discovery	Active
Neurology Diagnostics Program	Aptus Biosciences	Discovery	Active
GM1 Ganglioside-based Therapies	TRB Chemedica International	Commercial / Development	Active
Undisclosed Neurology Programs	BridGene Biosciences	Discovery	Active
iPSC Platform Programs	Evotec	Preclinical Research	Active
ExacTcell Platform	Tevogen Bio	Discovery/Preclinical	Research